

LETTER



# Rapid temperature increases under isoflurane sedation

Lukas M. Müller-Wirtz<sup>1,2\*</sup> , Marius Graf<sup>1</sup>, Thomas Volk<sup>1,2</sup> and Andreas Meiser<sup>1</sup>

© 2023 The Author(s)

Dear Editor,

Impairment of thermoregulation by inhaled and intravenous anesthetics has been extensively studied and essentially all anesthetics blunt thermoregulatory responses [1]. Interestingly, isoflurane—unlike propofol—shows a non-linear dose response suggesting largely preserved thermoregulatory responses within low dose ranges [2, 3]. Fever may thus develop more rapidly under isoflurane sedation. Similarly, more prominent temperature increases were observed during dexmedetomidine compared to predominant propofol sedation [4]. We therefore compared characteristics of temperature increases between isoflurane and propofol sedation in a one-year cohort of critically ill patients treated at our surgical intensive care unit.

This study was approved by the responsible ethics committee (2020-11-23, 295/20, Saarland Medical Association, Saarbrücken, Germany). Patients were ventilated for at least 96 hours in 2019 and received isoflurane or propofol for at least 48 hours. Patient characteristics are presented in the electronic supplementary material (ESM, Tables S1 and S2). Core temperatures were measured via urinary catheter temperature probes, digitally collected, and validated by the responsible intensive care nurse. Frequency of fever and temperature increases were assessed with adjustments for age, sex, body mass index, opioid intake, length of sedation, Simplified Acute Physiology Score (SAPS) II on admission, and daily Sequential Organ Failure Assessment (SOFA) score using logistic or linear generalized estimating equations regression.


Overall, 97 patients were included; 13 received isoflurane, 21 received propofol, and 63 received both sedatives sequentially on different sedation days. Across a total of 725 sedation days, isoflurane was administered on 257 (35%) and propofol on 468 (65%) days. Fever defined by core temperatures  $\geq 38.5^{\circ}\text{C}$  was twice as common in isoflurane-sedated patients: 41/257 days (16%) vs. 41/468 days (9%); odds ratio [95% confidence interval (CI)]: 2.4 [1.1, 5.1],  $p=0.021$ .

Temperature increases on fever days were more rapid under isoflurane, and both the fever threshold ( $\geq 38.5^{\circ}\text{C}$ ) and peak temperatures were reached more quickly: average difference [95% CI]:  $-320$  minutes [ $-454, -187$ ],  $p<0.001$ ;  $-302$  minutes [ $-465, -138$ ],  $p<0.001$  (Fig. 1). Maximum increases observed within 1 or 2 hours were significantly greater under isoflurane than propofol sedation:  $0.13^{\circ}\text{C}/\text{h}$  [0.02, 0.23],  $p=0.019$ ;  $0.17^{\circ}\text{C}/2\text{h}$  [0.05, 0.29],  $p=0.006$  (Fig. 1). Baseline temperatures were slightly higher in isoflurane-sedated patients:  $0.33^{\circ}\text{C}$  [0.07, 0.59],  $p=0.012$ ; but peak temperatures were similar:  $0.07^{\circ}\text{C}$  [ $-0.09, 0.23$ ],  $p=0.407$ . Procalcitonin and leucocyte count on fever days indicated infections but were similar with each sedation. Symptoms of malignant hyperthermia (e.g., unexplained increases in end-tidal carbon dioxide, muscle rigidity, increased laboratory markers of muscle damage) did not occur.

Our findings are consistent with drug-induced impairment of thermoregulatory responses, such as vasoconstriction and shivering. Whereas typical sedative propofol plasma concentrations of 2–4  $\mu\text{g}/\text{ml}$  correspond to a decrease in the vasoconstriction threshold of 1.2–2.4 $^{\circ}\text{C}$ , typical sedative end-tidal isoflurane concentrations of 0.3–0.5% correspond to a decrease less than 1 $^{\circ}\text{C}$  [2, 3]. In addition, most of the isoflurane-induced thermoregulatory impairment becomes only apparent when end-tidal concentrations exceed 0.5% [3]. Consistently, lower

\*Correspondence: lukas.mueller-wirtz@uks.eu

<sup>1</sup> Department of Anaesthesiology, Intensive Care and Pain Therapy, Saarland University Medical Center and Saarland University Faculty of Medicine, 66421 Homburg, Saarland, Germany  
Full author information is available at the end of the article



**Fig. 1** Body temperature increases—isoflurane versus propofol sedation. Differences in the characteristics of core temperature increases between patients receiving isoﬂurane or propofol were assessed by linear generalized estimating equations regression adjusted for age, sex, body mass index, opioid intake, length of sedation, SAPSII, and SOFA score.

average temperatures were reported with propofol versus isoflurane sedation [5].

More rapid temperature increases with isoflurane than with propofol sedation most likely reflect less-attenuated thermoregulation within sedative dose ranges and should not be attributed to malignant hyperthermia unless other typical symptoms occur. The clinical significance remains to be determined.

#### Supplementary Information

The online version contains supplementary material available at <https://doi.org/10.1007/s00134-023-07090-z>.

#### Author details

<sup>1</sup> Department of Anaesthesiology, Intensive Care and Pain Therapy, Saarland University Medical Center and Saarland University Faculty of Medicine, 66421 Homburg, Saarland, Germany. <sup>2</sup> Outcomes Research Consortium, Cleveland, OH 44195, USA.

#### Acknowledgements

We acknowledge Gudrun Wagenpfeil for her statistical advice.

#### Funding

Open Access funding enabled and organized by Projekt DEAL. The presented study was solely financed from institutional and/or departmental funds.

#### Data availability statement

Data analyzed for the current study are available from the corresponding author upon reasonable request.

#### Declarations

#### Conflicts of interest

LMMW received speaker fees and reimbursement of expenses for a scientific lecture on inhaled sedation of intensive care patients from Sedana Medical (Danderyd, Sweden). TV and AM received consulting fees from Sedana Medical.

#### Open Access

This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing,

adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by-nc/4.0/>.

#### Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Accepted: 26 April 2023

Published: 9 May 2023

#### References

1. Sessler DI (2008) Temperature monitoring and perioperative thermoregulation. *Anesthesiology* 109:318–338. <https://doi.org/10.1097/ALN.0b013e31817f6d76>
2. Matsukawa T, Kurz A, Sessler DI et al (1995) Propofol linearly reduces the vasoconstriction and shivering thresholds. *Anesthesiology* 82:1169–1180. <https://doi.org/10.1097/0000542-199505000-00012>
3. Xiong J, Kurz A, Sessler DI et al (1996) Isoflurane produces marked and nonlinear decreases in the vasoconstriction and shivering thresholds. *Anesthesiology* 85:240–245. <https://doi.org/10.1097/0000542-199608000-00003>
4. Grayson KE, Bailey M, Balachandran M et al (2021) The effect of early sedation with dexmedetomidine on body temperature in critically ill patients. *Crit Care Med* 49:1118–1128. <https://doi.org/10.1097/CCM.0000000000004935>
5. Meiser A, Volk T, Wallenborn J et al (2021) Inhaled isoflurane via the anaesthetic conserving device versus propofol for sedation of invasively ventilated patients in intensive care units in Germany and Slovenia: an open-label, phase 3, randomised controlled, non-inferiority trial. *Lancet Respir Med* 9:1231–1240. [https://doi.org/10.1016/S2213-2600\(21\)00323-4](https://doi.org/10.1016/S2213-2600(21)00323-4)